Abstract Purpose: Erlotinib (Tarceva, OSI-774) is a potent and specific inhibitor of the
HER1/epidermal growth factor receptor (EGFR) tyrosine kinase. In phase II clinical studies …

Lenvatinib is an inhibitor of multiple receptor tyrosine kinases that was recently authorized
for first-line treatment of hepatocellular carcinoma (HCC). However, the clinical benefits …

BACKGROUND: Epidermal growth factor receptor (EGFR) and vascular endothelial growth
factor (VEGF) are rational targets for therapy in hepatocellular cancer (HCC). METHODS …

Epidermal growth factor receptor (EGFR), which promotes cell survival and division, is found
at abnormally high levels on the surface of many cancer cell types, including many cases of …

Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …

Purpose: The insulin-like growth factor (IGF) signaling axis is frequently dysregulated in
hepatocellular carcinoma (HCC). Therefore, we investigated whether the specific targeting …

Epidermal growth factor receptor (EGFR)‐and type 1 insulin‐like growth factor receptor (IGF‐
1R)‐dependent pathways are up‐regulated in hepatocellular carcinoma (HCC), and cross …

Erlotinib is an orally available, reversible tyrosine kinase inhibitor of the epidermal growth
factor receptor. Encouraging activity as a single agent and in combination with other …

Purpose Epidermal growth factor receptor/human epidermal growth factor receptor 1 and
ligand expression is common in biliary cancers (BILI) and may be associated with worse …

BACKGROUND/AIMS: Epidermal growth factor receptor (EGFR) signaling has been
implicated in the genesis and progression of cholangiocarcinoma. However, the …